FTC Goes After Nevada Drug Firm

     RENO, Nev. (CN) – The Federal Trade Commission ordered two Nevada-based companies to stop making false claims about their pricey wart-removal and weight-loss products.
     The FTC sued Solace International and Bioscience Research Institute on Dec. 10 in Federal Court. They share the same address in Reno and both are run by Aaron Lilly, the FTC says in its request for an injunction.
     Among their products are DermaTend Ultra wart remover, which costs $69.95 for a 10-gram container; and Lipidryl for weight loss, which costs $129.99 for a 3-month supply, according to the lawsuit.
     The FTC doubts the efficacy of the products; says that the so-called “independent” testimonials in ads are not independent at all, but are paid promotions; questions the advertised “97 percent success rate” for DermaTend; and the claim that Lipidryl was “tested in a clinical study of over 100 overweight subjects” who lost an average of 28 lbs. in 10 weeks.
     The FTC claims the ads for both products are misleading and violate the FTC Act.
     It seeks disgorgement of ill-gotten gains, restitution and an injunction.

%d bloggers like this: